Watch hVIVO’s July 2024 Capital Markets Day here
We are a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.
Yamin 'Mo' Khan
CEO at hVIVO
"The broader CRO industry has been impacted by macroeconomic and sector-specific headwinds, and hVIVO is no exception. However, we are greatly encouraged by the early success of our diversification strategy and by the strength of our pipeline, with the aggregate value of customer proposals submitted in H1 2025 exceeding FY24. Looking ahead we are focused on finalising the integration of CRS and Cryostore into the Group, realising further synergies presented by these bolt-ons, converting our pipeline into revenue, and positioning the business to return to sustainable growth in 2026 and beyond."
H1 25 Revenue
H1 25 EBITDA Margin
Cash 30 June 2025
FY24 Guidance
Sign up to our emails and follow us on social media to keep up to date with hVIVO.